TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26471409

Group type: EXPERIMENTAL
Intervention: Corn Soya Blend Plus (CSBP)
Number of subjects: 288
Study: 24276303

Group type: EXPERIMENTAL
Intervention: Supervised, periodized exercise training with a personal trainer (TRAINED)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Self-directed training (SELF)
Number of subjects: 34
Study: 21570204

Group type: EXPERIMENTAL
Intervention: Continuous 7‐days‐a‐week pelvic irradiation (1.6 Gy daily for Group A, 1.8 Gy daily for Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous 7‐days‐a‐week pelvic irradiation
Number of subjects: 30
Study: 19617657

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid, 600 mg . day(‐1), for 8 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (T(CON))
Number of subjects: 33
Study: 17426529

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion SR generic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion SR brand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16320557

Group type: EXPERIMENTAL
Intervention: Microlaparoscopy under sedation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Microlaparoscopy under general anesthesia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 54
Study: 12470353

Group type: EXPERIMENTAL
Intervention: Transfer of a single zona-free blastocyst on day 5
Number of subjects: 420

Group type: COMPARATOR
Intervention: Transfer of a single zona-intact embryo
Number of subjects: 420
Study: 9432078

Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks olfactory test
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dirhinic testing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Monorhinic testing
Number of subjects: 63
Study: 8082553

Group type: EXPERIMENTAL
Intervention: Desipramine 150 mg daily
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Amantadine 300 mg daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 2815804

Group type: EXPERIMENTAL
Intervention: Hyperthermic perfusion with Melphalan (42 degrees C)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (wide excision and lymph node dissection)
Number of subjects: 107
Study: 807698

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vitamin D (4,000 IU daily for two months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vitamin D (single large oral dose)
Number of subjects: 36
Study: 31132795

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 3005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Adverse events (CNS-related)
Number of subjects: 3005
Study: 27389174

Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg plus fludarabine and cyclophosphamide (FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg plus fludarabine and cyclophosphamide (FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofatumumab pharmacokinetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline patient/disease factors
Number of subjects: 0
Study: 25800753

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 711

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 711
Study: 23691002

Group type: EXPERIMENTAL
Intervention: Selective transurethral resection of the prostate (STURP) combined with transurethral incision of the bladder neck (TUIBN)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 124
Study: 22221440

Group type: EXPERIMENTAL
Intervention: Single-dose montelukast (4 or 5 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19575797

Group type: EXPERIMENTAL
Intervention: artemisinin/naphtoquine (AN)
Number of subjects: 122

Group type: COMPARATOR
Intervention: artemether/lumefantrine (AL)
Number of subjects: 122
Study: 17301298

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (including lithotripsy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Surgical drainage (operative pancreaticojejunostomy)
Number of subjects: 39
Study: 15166532

Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: HIV-HBV
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: HIV-HCV
Number of subjects: 692
Study: 11479154

Group type: EXPERIMENTAL
Intervention: CRF patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ESRD-HD patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: PBMCs of ESRD-HD patients after IL-4 and IL-10 neutralization
Number of subjects: 3
Study: 9744445

Group type: EXPERIMENTAL
Intervention: Group A (n = 20, 2 minutes waiting time between FDEs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (n = 10, 10 minutes waiting time between FDEs)
Number of subjects: 30
Study: 8067808

Group type: COMPARATOR
Intervention: Mefloquine alone (750 mg immediately, followed by 500 mg 6 h later)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Artesunate followed by mefloquine (800 mg artesunate over 2 days, followed by 750 mg mefloquine)
Number of subjects: 125
Study: 2722726

Group type: EXPERIMENTAL
Intervention: Intravenous cefmetazole
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous cefoxitin
Number of subjects: 89
Study: 770364

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 30469158

Group type: EXPERIMENTAL
Intervention: gemcitabine+capecitabine or streptozotocin (both with or without mitotane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: local therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: combination of etoposide, doxorubicin and cisplatin (plus mitotane)
Number of subjects: 0
Study: 30536648

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 33
Study: 27872034

Group type: EXPERIMENTAL
Intervention: Short answer questions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Full video
Number of subjects: 49

Group type: COMPARATOR
Intervention: Logic puzzles
Number of subjects: 49
Study: 25015215

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg monthly
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg PRN
Number of subjects: 1098
Study: 22311988

Group type: EXPERIMENTAL
Intervention: Family intervention to promote effective parenting
Number of subjects: 186
Study: 20147739

Group type: EXPERIMENTAL
Intervention: Participants with possible MCI
Number of subjects: 2355

Group type: COMPARATOR
Intervention: Cognitively normal participants
Number of subjects: 2355
Study: 17635414

Group type: EXPERIMENTAL
Intervention: COP(ant) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: COP(post) condition
Number of subjects: 0
Study: 15309422

Group type: EXPERIMENTAL
Intervention: Abacor (25 g soy protein with soy fiber and phospholipids)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: SuproSoy (25 g soy protein without soy fiber and phospholipids)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (25 g milk protein)
Number of subjects: 121
Study: 12407532

Group type: COMPARATOR
Intervention: Motility (−) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Motility (+) group
Number of subjects: 20
Study: 10487488

Group type: EXPERIMENTAL
Intervention: Serum total sialic acid (S‐TSA)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Orosomucoid
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Alpha1‐antitrypsin
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: S‐TSA in a conditional multiple logistic regression model
Number of subjects: 310
Study: 8918079

Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 to 6 million units of recombinant IFN-alpha 2b or lymphoblastoid IFN-alpha, given 3 times weekly for 12 to 36 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: IFN-alpha (total dose above 215 MU)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: IFN-alpha (treatment for at least 24 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: IFN-alpha (non-genotype 1b/II HCV infection)
Number of subjects: 27
Study: 2226690

Group type: EXPERIMENTAL
Intervention: Antagonist muscle vibration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shortening agonist muscle vibration
Number of subjects: 0
Study: 7087285

Group type: EXPERIMENTAL
Intervention: Infusion of amino acids and glucose (39.5 g of amino acids and 200 g of glucose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline infusion (800 ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Infusion of amino acids and glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 8
Study: 31559808

Group type: EXPERIMENTAL
Intervention: Urban environment
Number of subjects: 7974

Group type: COMPARATOR
Intervention: Rural environment
Number of subjects: 7974

Group type: EXPERIMENTAL
Intervention: Both environments
Number of subjects: 7974
Study: 29318862

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Chengshan (BL 57), Dachangshu (BL 25), and Erbai (EX-UE 2) for 30 min each day for 3 days after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment after surgery (Control group)
Number of subjects: 60
Study: 25601014

Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy with indigo carmine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Chromocolonoscopy plus standard colonoscopy
Number of subjects: 78
Study: 23838425

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) in ACS
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in ACS
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) in SAP
Number of subjects: 2705

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) in SAP
Number of subjects: 2705
Study: 22302014

Group type: EXPERIMENTAL
Intervention: Pregabalin (150‐600 mg/day)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 356
Study: 20134142

Group type: EXPERIMENTAL
Intervention: Itraconazole prophylaxis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 40
Study: 18271232

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment at Sanyinjiao (SP 6), Fenglong (ST 40), Yinlingquan (SP 9), once a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Allopurinol, oral administration, twice a day, 100 mg each time
Number of subjects: 90

Group type: COMPARATOR
Intervention: Probenecid, oral administration, twice daily, 0.25 g each time
Number of subjects: 90
Study: 16324236

Group type: EXPERIMENTAL
Intervention: Huntington's disease patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 12196359

Group type: EXPERIMENTAL
Intervention: Biweekly CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 2 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2), prednisolone 100 mg for 5 days every 3 weeks)
Number of subjects: 70
Study: 9785072

Group type: EXPERIMENTAL
Intervention: Tramadol (10 mg bolus)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Morphine (1 mg bolus)
Number of subjects: 38
Study: 7616027

Group type: EXPERIMENTAL
Intervention: Preliminary and continuous hemodialysis (HD group)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (no hemodialysis)
Number of subjects: 5
Study: 2239789

Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Vegetable oil placebo
Number of subjects: 27
Study: 6105714

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triazolam 1.0 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg
Number of subjects: 120
Study: 31168657

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg subcutaneously monthly for 12 months, followed by denosumab 60 mg subcutaneously every 6 months for 24 months
Number of subjects: 492
Study: 28078741

Group type: EXPERIMENTAL
Intervention: Art brut therapy program called go beyond the schizophrenia (GBTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26611765

Group type: COMPARATOR
Intervention: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 10 days
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, bismuth subcitrate potassium, tetracycline, and metronidazole) for 10 days
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 218
Study: 23430010

Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity aerobic exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 26
Study: 21483019

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study: 19132781

Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study: 19665101

Group type: EXPERIMENTAL
Intervention: Meal replacements (MR) during weight loss maintenance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 60
Study: 15748230

Group type: EXPERIMENTAL
Intervention: Low-dose DX-9065a
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: High-dose DX-9065a
Number of subjects: 402

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Higher concentrations of DX-9065a
Number of subjects: 402
Study: 12572381

Group type: EXPERIMENTAL
Intervention: Kesuning Granule (KSNG) 8 g, three times a day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Jinbei Tankeqing Granule (JBTKQ) 7 g, three times a day
Number of subjects: 120
Study: 9892479

Group type: EXPERIMENTAL
Intervention: Captopril (ACE inhibitor) therapy administered 48 to 72 hours postoperatively in group B (103 patients)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (group A, 195 patients) continued on IABP and inotropes alone
Number of subjects: 298
Study: 8558900

Group type: EXPERIMENTAL
Intervention: Adjustment for person-level covariates
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adjustment for community-level covariates
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Self-reported behaviors
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Belief and attitude items
Number of subjects: 15
Study: 2359747

Group type: EXPERIMENTAL
Intervention: Airstream Helmet (main filter P2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sundström Mask (main filter P3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No respirator
Number of subjects: 42
Study: 709092

Group type: COMPARATOR
Intervention: Unrestricted diet (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg cholesterol diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 600 mg cholesterol diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg cholesterol diet (after 600 mg diet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g daily) added to 100 mg cholesterol diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plant sterols (3 g daily) added to 600 mg cholesterol diet
Number of subjects: 15
Study: 12199394

Group type: EXPERIMENTAL
Intervention: Voice amplification using the ChatterVox portable amplifier (VA, n = 15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vocal hygiene (VH, n = 15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nontreatment control group (n = 14)
Number of subjects: 44
Study: 31816818

Group type: EXPERIMENTAL
Intervention: Personalized exercise training program based on ACE IFT model guidelines (12 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-exercise control group (usual lifestyle habits)
Number of subjects: 150
Study: 30115422

Group type: EXPERIMENTAL
Intervention: DANAMI-3 participants (n=1,603)
Number of subjects: 2490

Group type: COMPARATOR
Intervention: DANAMI-3 nonparticipants (n=887)
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: TMMB day 0 to 30
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: TMMB day 31 to 365
Number of subjects: 2490
Study: 26757216

Group type: EXPERIMENTAL
Intervention: 40 mg atomoxetine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 mg citalopram
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 25006707

Group type: EXPERIMENTAL
Intervention: SimDE (virtual case-based simulation)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 341
Study: 22382254

Group type: EXPERIMENTAL
Intervention: Discharge letter with additional information on PPI review aligned to published guidelines
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual practice discharge letter without additional information
Number of subjects: 51
Study: 20453057

Group type: EXPERIMENTAL
Intervention: Information‐Motivation‐Behavioral (IMB) skills model‐based intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 152
Study: 17563187

Group type: EXPERIMENTAL
Intervention: Experimental group engaged in adaptive social-cognitive processes through writing
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Study 1 (no specific intervention mentioned)
Number of subjects: 286
Study: 16401982

Group type: EXPERIMENTAL
Intervention: Limited resection (segment or wedge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited resection (intentional)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 0
Study: 12145003

Group type: EXPERIMENTAL
Intervention: Mono diet (40% fat; 11% saturated, 19% monounsaturated, 8% polyunsaturated fatty acids)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Poly diet (34% fat; 11% saturated, 10% monounsaturated, 10% polyunsaturated fatty acids)
Number of subjects: 31
Study: 10099910

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8848904

Group type: EXPERIMENTAL
Intervention: Combination of oral promethazine (10 mg) and transdermal scopolamine (1.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral diazepam (5‐15 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral promethazine (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of oral promethazine and transdermal scopolamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 2193273

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring with a guard ring tocodynamometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine transmission of uterine activity monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported signs and symptoms of preterm labor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily objective uterine activity data
Number of subjects: 0
Study: 358765

Group type: EXPERIMENTAL
Intervention: Ferro-Retard (100 mg ferrous sulphate)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ferro-Retard (100 mg Fe2+)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sustained release tablets
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo, rapidly disintegrating and sustained release ferrous sulphate tablets
Number of subjects: 140
Study: 31786869

Group type: EXPERIMENTAL
Intervention: Cisplatin and nimotuzumab combined with concurrent chemoradiotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cisplatin combined with concurrent chemoradiotherapy
Number of subjects: 92
Study: 30388762

Group type: EXPERIMENTAL
Intervention: DGA-based diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study: 25483419

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (L)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous hydralazine (H)
Number of subjects: 29
Study: 24528351

Group type: EXPERIMENTAL
Intervention: Photographic educational materials
Number of subjects: 76

Group type: COMPARATOR
Intervention: List of foods
Number of subjects: 76
Study: 22214231

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 69
Study: 20981505

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy (Soy-)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy (Soy+)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk protein (Milk)
Number of subjects: 30
Study: 18332608

Group type: EXPERIMENTAL
Intervention: Pitavastatin treatment
Number of subjects: 117
Study: 16279903

Group type: EXPERIMENTAL
Intervention: 4.8 g/day mesalamine (800 mg tablet)
Number of subjects: 268

Group type: COMPARATOR
Intervention: 2.4 g/day mesalamine (400 mg tablet)
Number of subjects: 268
Study: 11477042

Group type: EXPERIMENTAL
Intervention: Academic detailing (practice visit about EBM)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (visited at a later date)
Number of subjects: 132
Study: 9757873

Group type: EXPERIMENTAL
Intervention: Breast-feeding practices
Number of subjects: 4118
Study: 8142092

Group type: EXPERIMENTAL
Intervention: 3 mg of epidural morphine
Number of subjects: 20